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To the Editors
Rapid influenza diagnostic tests (RIDTs) are often used at point-of-care due to their ease of 
use and rapidly available results. Most tests are lateral flow immunoassays that detect 
chromatographic changes if an influenza antigen is present in the respiratory specimen. 
These tests have high specificity (therefore, a positive is almost certainly a true positive) but 
low sensitivity (therefore, will often miss true cases).1,2 A newer immunofluorescence 
assay, Sofia A+B FIA (Quidel, San Diego, CA), demonstrated increased sensitivity but 
maintained high specificity.3 However, on December 3, 2012, Quidel issued a voluntary 
recall of certain lots of Sofia A+B because of false positive results.4
In August 2011, we began a prospective cohort study of children aged ≤36 months at Queen 
Sirikit National Institute of Child Health, the largest pediatric referral hospital in Thailand. 
Children (equal numbers of high risk and healthy) are followed for 2 years and parents 
contacted weekly to inquire about whether their child had acute respiratory illness. Ill 
children came to the hospital and had a combined nasal and throat swab collected and tested 
for influenza viruses by realtime reverse transcription polymerase chain reaction (rRT-
PCR).5 In addition, a separate nasal swab was taken and tested using 1 of 2 RIDTs made by 
Quidel (QuickVue A+B during August 2011 to January 20, 2013; Sofia A+B during January 
21, 2013 to May 2013).
Of the 1152 specimens tested with QuickVue A+B, 59 (5.1%) were positive by rRT-PCR. 
Compared with rRT-PCR, Quick-Vue A+B had a sensitivity of 55.9% (33/59; 95% 
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confidence interval (CI): 42.4–68.8%) and a specificity of 99.4% (1086/1093; 95% CI: 
98.7–99.7%). Seven (0.6%) were false positive on QuickVue A+B. Of the 370 specimens 
tested with Sofia A+B, 12 (3.2%) were positive by rRT-PCR. Compared with rRT-PCR, 
Sofia had a sensitivity of 100% (12/12; 95% CI: 73.5–100.0%) and a specificity of 61.2% 
(219/358; 95% CI: 55.9–66.3%). One-hundred thirty nine (38.8%) were false positive on 
Sofia. Of the 139 false positives, 123 (88.5%) were influenza B and 16 were influenza A. 
There was no difference in the time between illness onset and specimen collection date 
between true and false positives (median days = 2; P = 0.96), nor was there a difference 
between the prevalence of influenza during the 2 periods (5.1% vs. 3.2%, P = 0.1). Two lots 
of the Sofia assay were used and both had poor specificity (data not shown).
We learned that the assay lots we purchased were made after the recognized problem that 
led to the recall was corrected. Nevertheless, our data suggest that continuing problems 
exist. We share these data to alert others using this assay to the risk of false positives.
Our findings further support the limitations in using RIDTs for clinical decision making.6 In 
Thailand, the Clinical Practice Guidelines recommend oseltamivir treatment for 2 groups of 
patients: (1) patients with complicated or severe influenza (ie, pneumonia, alteration of 
conscious, loss of appetite or dehydration and symptoms worsening after 48 hours of illness) 
and (2) patients with a high risk of having severe influenza (ie, pregnancy, obesity or 
chronic medical conditions). They also state that oseltamivir should also be considered in 
children <2 years of age or persons >65 years of age. In Thailand, the use of RIDTs is not 
recommended for deciding on a course of treatment. Further, we caution that newer RIDTs 
using immunofluorescence may need additional field evaluations.
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